drugset / Trial / NCT06118684
Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this trial is to assess the potential key drug-drug interactions with EP395 in the clinical setting.
Timeline
- Start
- 2023-10-23
- Primary completion
- 2024-01-02
- Completion
- 2024-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | 0.25 mg | — |
| Subject | Midazolam | Small molecule | 4 mg | Oral |
| Subject | Verapamil | Other / unclassified | 120 mg | — |
| Subject | glasmacinal | Small molecule | 125 mg | Oral |
| Subject | glasmacinal | Small molecule | 375 mg | Oral |